Immunofluorescent analysis of ErbB4 (green) showing staining in the cytoplasm of SK-BR-3 cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with an ErbB4 monoclonal antibody (Product # MA1-861) in 3% BSA-PBS at a dilution of 1:50 and incubated overnight at 4°C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. Actin was stained using Alexa Fluor 554 (red) and nuclei were stained with Hoechst or DAPI (blue). Images were taken at a magnification of 60x.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human, Mouse, Not Applicable|
|Host / Isotype||Mouse / IgG2b|
|Immunogen||Synthetic Peptide: C R(1250) S T L Q H P D Y L Q E Y S T(1264)|
|Storage buffer||PBS with 1mg/ml BSA|
|Contains||0.05% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||0.5-2ug per test|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100|
|Immunoprecipitation (IP)||Assay dependent|
|Western Blot (WB)||1:100-1:500|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA1-861 detects Her-4 from human and mouse samples.
MA1-861 has been successfully used in immunoprecipitation, immunohistochemical, and Western blotting procedures. By Western blot, this antibody detects ~185 kDa protein representing Her-4 from human A431 cell and mouse NIH3T3/HER4 cell extracts.This antibody has also been used in immunohistochemical, using paraffin embedded mouse NIH3T3 cells.
MA1-861 immunizing peptide corresponds to amino acid residues 1250 to 1264 of human Her-4 oncoprotein.
Her-4, also known as c-erbB-4 and v-erbB-4, is a Type 1 membrane protein found in numerous cell types. It is a member of the EGF receptor protein family, and is activated by neuregulins and NTAK. Her-4 levels have been found to be elevated in certain human tumor cell lines suggesting that it may play a role in some malignancies. Her-4 is a receptor for heregulin and is capable of mediating HGL-stimulated tyrosine phosphorylation of itself.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
MA1-861 was used in immunohistochemistry to study the prognostic and clinical value of Ki67 proliferation index and HER2 expression in luminal breast cancer
|Jerjees DA,Alabdullah M,Green AR,Alshareeda A,Macmillan RD,Ellis IO,Rakha EA||Breast cancer research and treatment (145:317)||2014|
Expression of the epidermal growth factor system in human middle ear cholesteatoma.
MA1-861 was used in immunohistochemistry to study the expression of the EGFR system in patients with middle ear cholesteatoma
|Thorup MB,Munk M,Poulsen SS,Gaihede M,Nexo E,Sorensen BS,Ovesen T||Acta oto-laryngologica (134:124)||2014|
CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro.
MA1-861 was used in immunohistochemistry to study the role and prognostic value of ErbB4 CYT-1 isoform expression in serous ovarian cancer
|Paatero I,Lassus H,Junttila TT,Kaskinen M,Bützow R,Elenius K||Gynecologic oncology (129:179)||2013|
Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
MA1-861 was used in immunohistochemistry to study the clinicopathological significance of cystatin M loss in invasive breast cancer
|Ko E,Park SE,Cho EY,Kim Y,Hwang JA,Lee YS,Nam SJ,Bang S,Park J,Kim DH||Breast cancer research : BCR (12:null)||2011|
Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.
MA1-861 was used in immunohistochemistry to study the prognostic value of c-erbB2 expression in anaplastic astrocytomas
|Gulati S,Ytterhus B,Granli US,Gulati M,Lydersen S,Torp SH||Diagnostic pathology (5:null)||2010|
HER-family gene amplification and expression in resected pancreatic cancer.
MA1-861 was used in immunohistochemistry to study the immunohistochemical expression of HER1-4 and gene amplification of HER2 in resected pancreatic cancer
|te Velde EA,Franke AC,van Hillegersberg R,Elshof SM,de Weger RW,Borel Rinkes IH,van Diest PJ||European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (35:1098)||2009|
The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.
MA1-861 was used in immunohistochemistry to study the role of HER4/4ICD and BH3-only protein in tamoxifen-induced apoptosis
|Naresh A,Thor AD,Edgerton SM,Torkko KC,Kumar R,Jones FE||Cancer research (68:6387)||2008|
Expression of tumor necrosis factor alpha converting enzyme in endocrine cancers.
MA1-861 was used in immunohistochemistry to study the immunohistochemical expression of TACE in endocrine cancers and its potential role in breast cancer apoptosis
|Kirkegaard T,Naresh A,Sabine VS,Tovey SM,Edwards J,Dunne B,Cooke TG,Jones FE,Bartlett JM||American journal of clinical pathology (129:735)||2008|
Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer.
MA1-861 was used in immunohistochemistry to investigate the association of expression of various members of ErbB family receptors with progression of urothelial carcinoma
|Kassouf W,Black PC,Tuziak T,Bondaruk J,Lee S,Brown GA,Adam L,Wei C,Baggerly K,Bar-Eli M,McConkey D,Czerniak B,Dinney CP||The Journal of urology (179:353)||2008|
Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study.
MA1-861 was used in immunohistochemistry to study the coexpression of c-erbB 1-4 receptor proteins in human glioblastomas
|Torp SH,Gulati S,Johannessen E,Dalen A||Journal of experimental and clinical cancer research : CR (26:353)||2007|
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
MA1-861 was used in immunohistochemistry to identify prognostic indicators of response/resistance to trastuzumab in metastatic breast cancer
|Giuliani R,Durbecq V,Di Leo A,Paesmans M,Larsimont D,Leroy JY,Borms M,Vindevoghel A,Jerusalem G,D'Hondt V,Dirix L,Canon JL,Richard V,Cocquyt V,Majois F,Reginster M,Demol J,Kains JP,Delree P,Keppens C,Sotiriou C,Piccart MJ,Cardoso F||European journal of cancer (Oxford, England : 1990) (43:725)||2007|
Expression of the epidermal growth factor system in endometrioid endometrial cancer.
MA1-861 was used in immunohistochemistry to study the expression of the EGF system in endometrioid endometrial cancer
|Ejskjaer K,Sørensen BS,Poulsen SS,Forman A,Nexø E,Mogensen O||Gynecologic oncology (104:158)||2007|
Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition.
MA1-861 was used in immunohistochemistry to study the role of erbB family phosphorylation in osteosarcoma
|Hughes DP,Thomas DG,Giordano TJ,McDonagh KT,Baker LH||Pediatric blood and cancer (46:614)||2006|
Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study.
MA1-861 was used in immunohistochemistry to study the immunohistochemical expression of EGFR family members in ovarian granulosa cell tumors
|Leibl S,Bodo K,Gogg-Kammerer M,Hrzenjak A,Petru E,Winter R,Denk H,Moinfar F||Gynecologic oncology (101:18)||2006|
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
MA1-861 was used in immunohistochemistry to study the morphological and immunophenotypic features of breast carcinomas with basal and myoepithelial differentiation
|Rakha EA,Putti TC,Abd El-Rehim DM,Paish C,Green AR,Powe DG,Lee AH,Robertson JF,Ellis IO||The Journal of pathology (208:495)||2006|
Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas.
MA1-861 was used in immunohistochemistry to study the prognostic value of HER3 and HER4 expression in colorectal adenocarcinomas
|Kountourakis P,Pavlakis K,Psyrri A,Rontogianni D,Xiros N,Patsouris E,Pectasides D,Economopoulos T||BMC cancer (6:null)||2006|
The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.
MA1-861 was used in immunohistochemistry to study the role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer
|Edwards J,Traynor P,Munro AF,Pirret CF,Dunne B,Bartlett JM||Clinical cancer research : an official journal of the American Association for Cancer Research (12:123)||2006|
NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis.
MA1-861 was used in immunohistochemistry to investigate the association of NRG1 gene rearrangements with poor prognosis in breast cancer treatment
|Prentice LM,Shadeo A,Lestou VS,Miller MA,deLeeuw RJ,Makretsov N,Turbin D,Brown LA,Macpherson N,Yorida E,Cheang MC,Bentley J,Chia S,Nielsen TO,Gilks CB,Lam W,Huntsman DG||Oncogene (24:7281)||2005|
Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.
MA1-861 was used in immunohistochemistry to study the prognostic value of EGFR family member expression and phospo-Akt levels in cervical carcinoma treated with radiation therapy
|Lee CM,Shrieve DC,Zempolich KA,Lee RJ,Hammond E,Handrahan DL,Gaffney DK||Gynecologic oncology (99:415)||2005|
|Not Applicable||Not Cited||
High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses.
MA1-861 was used in immunohistochemistry to discuss revising the classification systems for breast cancer
|Abd El-Rehim DM,Ball G,Pinder SE,Rakha E,Paish C,Robertson JF,Macmillan D,Blamey RW,Ellis IO||International journal of cancer (116:340)||2005|
Expression of the epidermal growth factor system in human endometrium during the menstrual cycle.
MA1-861 was used in immunohistochemistry to study the importance of the EGF system in the growth of the human endometrium
|Ejskjaer K,Sørensen BS,Poulsen SS,Mogensen O,Forman A,Nexø E||Molecular human reproduction (11:543)||2005|
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.
MA1-861 was used in immunohistochemistry to investigate the efficacy of the combination of paclitaxel, carboplatin and gefitinib against advanced breast cancer
|Fountzilas G,Pectasides D,Kalogera-Fountzila A,Skarlos D,Kalofonos HP,Papadimitriou C,Bafaloukos D,Lambropoulos S,Papadopoulos S,Kourea H,Markopoulos C,Linardou H,Mavroudis D,Briasoulis E,Pavlidis N,Razis E,Kosmidis P,Gogas H||Breast cancer research and treatment (92:1)||2005|
Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
MA1-861 was used in immunohistochemistry to study the frequency and prognostic value of coexpression of HER-1, HER-2, HER-3, and HER-4 by breast carcinoma
|Wiseman SM,Makretsov N,Nielsen TO,Gilks B,Yorida E,Cheang M,Turbin D,Gelmon K,Huntsman DG||Cancer (103:1770)||2005|
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.
MA1-861 was used in immunohistochemistry to study the expression of EGFR family members in invasive breast cancers
|Abd El-Rehim DM,Pinder SE,Paish CE,Bell JA,Rampaul RS,Blamey RW,Robertson JF,Nicholson RI,Ellis IO||British journal of cancer (91:1532)||2004|
Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation.
MA1-861 was used in immunohistochemistry to report on a case of a patient with HER2-overexpressing metastatic breast cancer highly sensitive to trastuzumab treatment
|Mano MS,Awada A,Minisini A,Durbecq V,Di Leo A,Piccart M||Breast (Edinburgh, Scotland) (13:347)||2004|
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
MA1-861 was used in immunohistochemistry to investigate a specific chromosomal aberration in breast and pancreatic cancer cell lines
|Adélaïde J,Huang HE,Murati A,Alsop AE,Orsetti B,Mozziconacci MJ,Popovici C,Ginestier C,Letessier A,Basset C,Courtay-Cahen C,Jacquemier J,Theillet C,Birnbaum D,Edwards PA,Chaffanet M||Genes, chromosomes and cancer (37:333)||2003|
CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling.
MA1-861 was used in immunohistochemistry and western blot to study the role of CD44 in forming a HSPG/MMP7/HB-EGF/ErbB4 complex and its role in regulating female reproductive organ remodelling
|Yu WH,Woessner JF,McNeish JD,Stamenkovic I||Genes and development (16:307)||2002|
Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains.
MA1-861 was used in immunocytochemistry to study the localization and function of alternative ErbB4 intracellular domains
|Sundvall M,Peri L,Määttä JA,Tvorogov D,Paatero I,Savisalo M,Silvennoinen O,Yarden Y,Elenius K||Oncogene (26:6905)||2007|
H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent.
MA1-861 was used in western blot to investigate the mechanism for radioresistance induced by H-RAS V12 in HCT116 cells
|Carón RW,Yacoub A,Zhu X,Mitchell C,Han SI,Sasazuki T,Shirasawa S,Hagan MP,Grant S,Dent P||Molecular cancer therapeutics (4:243)||2005|
Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor.
MA1-861 was used in western blot to study the role of a dominant-negative EGFR in the radiosensitization of malignant glioma cells
|Lammering G,Valerie K,Lin PS,Mikkelsen RB,Contessa JN,Feden JP,Farnsworth J,Dent P,Schmidt-Ullrich RK||Clinical cancer research : an official journal of the American Association for Cancer Research (7:682)||2001|